An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
Editorial by Prof Manolis Tsiknakis, Coordinator of ProCAncer-I project The ProCAncer-I project has completed the first year of its lifecycle at the end of October 2021. With this brief note key results and achievements of the first year are summarized in the sequel....
Within the ProCancer-I project, a total of nine clinical needs will be addressed utilizing artificial intelligence (AI) models trained on ProstateNET – a unified repository of 1.5 million images of prostate MRI acquired across the consortium. In the current landscape...
ProCAncer-I aspires to create the largest interoperable, high-quality multi-parametric Magnetic Resonance Imaging (mpMRI) dataset worldwide/globally comprising more than 11.000 retrospective and more than 6.000 prospective mpMRI examinations, including clinical data,...
Interview with prof. Daniele Regge (Clinical Coordinator of the ProCancer-I project) Q: In the case of prostate cancer there are several tests that can help clinicians in the decision process, for example, prediction algorithms based on PSA blood test and biopsy. Why...
A brief historical survey of European state-of-play, the open issues and the ProCAncer-I approach Over the last decade, Artificial Intelligence (AI) solutions to support the whole value-chain of medical imaging[1] has experienced a considerable acceleration. This...
By the Fundacao D. Anna Sommer Champalimaud e Dr. Carloss Montez Champalimaud (CF) Champalimaud Foundation (CF) is a private non-profit Portuguese institution, inaugurated in 2010 with the aim of advancing basic and translational world-leading research in...
By the FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE) The FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE) is a Spanish non-profit organization that carries out...
By the Massachusetts General Hospital (The General Hospital Corp) (QTIM) Our lab, the Quantitative Translational Imaging in Medicine (QTIM) lab, at the Athinoula A. Martinos Center for Biomedical Imaging of the Massachusetts General Hospital (MGH), focuses on...
Newsletter #2 Contents
The ProCAncer-I project aims to revolutionize prostate cancer diagnosis and treatment through the power of artificial intelligence and advanced imaging. By creating a large, federated database of prostate MRI scans and clinical data, the project enables the...
ProCAncer-I results | Prof. Daniele Regge on clinical validation In this video, we present the results of the clinical validation of AI models that were developed during the ProCAncer-i Project. Clinical validation is a critical step to ensure that AI tools not only...
ProCAncer-I results | Prof. Papanikolaou on Prostanet including PI-QUAL Study and tools Since its inception, the ProCAncer-I project has aimed to establish a robust, ethically compliant AI platform—ProstateNet—to revolutionize prostate cancer (PCa) care through...
In the following AI-generated audio file, ProCAncer-I achievements are described in a simple way. Since its inception, the ProCAncer-I project has been on a mission to transform prostate cancer (PCa) care through advanced AI and ethically compliant data platforms. At...